Status:

TERMINATED

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

Lead Sponsor:

Astellas Pharma Inc

Collaborating Sponsors:

Agensys, Inc.

Conditions:

Carcinoma, Renal Cell

Kidney Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the diseas...

Detailed Description

Subjects will be enrolled sequentially into 5 planned dose cohorts according to a standard, dose escalation study design. A disease assessment will be performed at study week 5 (+/- 3 days) by the inv...

Eligibility Criteria

Inclusion

  • Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell carcinoma (including papillary, clear cell, and excluding transitional cell types) that is not amendable to cure by surgery or other means, and must have failed at least one prior systemic therapy, including but not limited to treatment with sunitinib, temsirolimus or sorafenib
  • Evaluable/Measureable disease according to Response Criteria for Solid tumors
  • Eastern Cooperative Group performance status of 0-1
  • Therapeutic anti-coagulation (PT, and/or INR, PTT) permitted, if clinically stable and \>/= 3 months from initiation

Exclusion

  • Past or present documented central nervous system (CNS) tumor or CNS metastasis
  • Use of investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer)
  • History of thromboembolic events and bleeding disorders \</= 3 months (e.g., DVT or PE)
  • Major Surgery (that requires general anesthesia) within 4 weeks of study enrollment

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT00816686

Start Date

October 1 2008

End Date

April 1 2010

Last Update

February 27 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Baltimore, Maryland, United States, 21231

2

New York, New York, United States, 10021